Plasminogen activator inhibitor 1 messenger RNA expression and molecular evidence for del(7)(q22) in uterine leiomyomas

Cancer Research

Volumn 56, Issue 13, 1996, Pages 3123-3128

  Sourla, Antigone ^a   Polychronakos, Constantin ^b   Zeng, Wendy Rong ^c   Nepveu, Alain ^c   Kukuvitis, Asterios ^b   Naud, Françoise ^d   Koutsilieris, Michael ^a,d  

^a LAVAL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CHROMOSOME 7Q; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MENSTRUAL CYCLE; MYOMETRIUM; NORTHERN BLOTTING; PRIORITY JOURNAL; UTERUS MYOMA; VASCULAR ENDOTHELIUM;

ADULT; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE DELETION; HETEROZYGOTE; HUMANS; LEIOMYOMA; MENSTRUAL CYCLE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYOMETRIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; UTERINE NEOPLASMS;

EID: 0029937005     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Towsend, D. E., Sparkes, R. S., and McClellan, M. D Unicellular histogenesis of uterine leiomyomas as detected by electrophoresis of glucose-6-phosphate dehydrogenase. Am. J. Obstet. Gynecol, 107: 1168-1173, 1970.
2. Buttram, V C. Uterine leiomyomata-aetiology, symptomatology, and management. In: C. C. Buttram (ed.), Gonadotropin Down-Regulation in Gynecological Practice, pp. 273-296 New York: Alan R Liss, 1986.
3. Eiletz, Z., Genz, T., Pollow, K., and Gollwitzer-Schimdt, M. Sex steroid levels in serum, myometrium, and fibromata in correlation with cytoplasmic receptors and 17β-HSD activity in different age-groups and phases of the menstrual cycle. Arch. Gynecol., 229: 13-28, 1980.
4. Otsuka, H. Shinohara, M., Kashiomura, M., Yoshiba, K., and Okamura, Y. A comparative study of the estrogen receptor ratio in myometrium and uterine leiomyomas Int. J Gynecol. Obstet., 29: 189-194, 1989.
5. Soules, M. R., and McCarthy, K. S., Jr. Leiomyomas: steroid receptor content, variation within normal menstrual cycles. Am. J. Obstet. Gynecol., 143: 6-11, 1982.
6. Tamaya, T., Fujimoto, J., and Okada, H. Comparison of cellular levels of receptors in uterine leiomyoma and myometrium. Acta Obstet. Gynecol. Scand., 64: 307-309, 1985.
7. Sadan, O., Van Iddeninge, B., Savage, N Van der Walt, L. A., and Zakut, H. Endocrine profile associated with estrogen and progesterone receptors in leiomyoma and normal myometrium Gynecol. Endocrinol., 4: 33-42, 1990.
8. Branton, D. D., Betyea, C. L , Stawn, E. Y , Novy, M. J , Burry, K. A., Harrington, M. S., Erickson, T. E., Warner, C., Keenan, E J., and Clinton, G. M. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas Am J. Obstet Gynecol , 169: 78-85, 1993.
9. Murphy, A A., Kettel, L M , Morales, A. J., Roberts, V. J., and Yen, S. S. Regression of uterine leiomyomata in response to the antiprogesterone RU486. J. Clin Endocrinol Metab., 76: 513-517, 1993.
10. Kitz, R. J., Rutgers, J., Phillips, J., Murugesapillai, M. L , and Kletzky, O A. Absence of a dose-dependent effect of leuprolide acetate on leiomyomata uteri size. Fertil. Steril., 61: 1021-1026, 1994
11. Gutmann, J. N., Thornton, K. L., Diamond, M. P., and Carcangiu, M. L Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil. Steril., 61: 622-626, 1994
12. Rein, M S., Friedman, A. J., Stuart, J. M., and Maclaughlin, D. T. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril., 53, 1018-1023, 1990.
13. Fedele, L., Versellini, P., Bianki, S , Brioschi, D., and Dortam M. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br. J. Obstet. Gynecol., 97: 393-396, 1990.
14. Biro, J. C. Estrogen-induced proteins: a new class of regulatory substances. Med. Hypotheses, 19: 199-228, 1986.
15. Koutsiliens, M. Pathophysiology of uterine leiomyomas. Biochem. Cell Biol., 70: 273-278, 1992.
16. Ghahary, A., and Murphy, L. J. Uterine insulin-like growth factor-1 receptors: regulation by estrogen and variation throughout the estrous cycle. Endocrinology, 125: 597-604, 1989.
17. Rein, M. S., Friedman, A. J., Pandjian, M. R., and Heffner, L. J. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist Obstet. Gynecol., 76: 388-394, 1990.
18. Vallenhoven, B. J., Herington, A. C., and Healy, D. L. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J. Clin. Endocrinol. Metab., 76: 1106-1110, 1993.
19. Giudice, L. C., Irwing, J. C., Dsupin, B. A., Pannier, E M., Jin, I H , Vu, T. H., and Hoffmann, A. R. Insulin-like growth factor I (IGF), IGF-binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod., 8 1796-1809, 1993.
20. Rossi, M. J., Chegini, N., and Masterson, B. J. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells:their action in smooth muscle cells in vitro. Endocrinology. 130: 1716-1727, 1992
21. Fayed, Y. M., Tsibris, G C. M., Langenberg, P. W., and Robertson, A. L., Jr. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab. Invest., 60: 30-37, 1989.
22. Harrisson-Woolrych, M. L., Charnock-Jones, D S., and Smith, S. K. Quantitation of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J. Clin. Endocrinol. Metab., 78: 1179-1184, 1994.
23. Koutsilieris, M. Human uterus-derived growth substances for rat bone cells and fibroblasts. Am. J. Obstet. Gynecol., 161: 1313-1336, 1989.
24. Koutsilieris, M., Michaud, J., and Nikolis, A. Preferential mitogenic activity for myoblast-like cells can be extracted from leiomyoma tissues. Am. J. Obstet. Gynecol , 163: 1665-1670, 1990.
25. Koutsilieris, M , Elmeliam, D., Frenette, G , and Maheux, R. Leiomyoma-derived growth factor for smooth-muscle cells. In Vivo, 6: 579-584, 1992.
26. Sourla, A , and Koutsilieris, M. Purification and partial sequencing of the major mitogen for smooth-muscle-like cells in leiomyoma extracts. J. Clin. Invest., 96: 751-758, 1995.
27. Nibert, M., and Heim, S. Uterine leiomyoma cytogenetics. Genes Chromosomes & Cancer, 2: 3-13, 1990.
28. Mark, J , Havel, G., Grepp, C., Danhlenfors, R , and Wedell, B Cytogenetical observations in human benign uterine leiomyomas. Anticancer Res., 8: 621-626, 1988
29. Sait, S. N. J., Gin, P. D., Ovanessoff, S., and Sandberg, A A. A uterine leiomyoma showing both t(12;14) and del(7) abnormalities. Cancer Genet. Cytogenet., 37: 157-161, 1989.
30. Ozisik, Y Y., Metoni, A M , Surti, U , and Sandberg, A A. Deletion 7q22 in uterine leiomyoma: a cytogenetic review Cancer Genet. Cytogenet., 71: 1-6, 1993.
31. Scherer, S W., Neufeld, E J , Lievens, P. M-J., Orkin, S. H., Kim, J., and Tsui, L-C Regional localization of the CCAAT displacement protein gene (CUTLI) to 7q22 by analysis of somatic cell hybrids. Genomics, 15: 695-696, 1993.
32. Bosma, P. J., van den Berg, E. A., and Kooistra, T. Human plasminogen activator inhibitor-1 gene promoter and structural gene nucleotide sequences. J. Biol. Chem. 251: 9129-9141, 1988.
33. Koutsiliens, M. Osteoblastic metastases in advanced prostate cancer cell biology and therapy. Crit Rev. Oncol. Hematol., 18: 51-64, 1995.
34. Koutsilieris, M., Frenette, G., Lazure, C , Lehoux, J-G., Govindan, M. V , and Polychronakos, C Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in the PA-III cell-induced osteoblastic metastases Anticancer Res., 13, 481-486, 1993.
35. Reyes-Moreno, C., Frenette, G , Boulanger, J., Lavergne, E., Govindan, M V., and Koutsilieris, M. Mediation of glucocorticoid receptor function by transforming growth factor beta 1 expression in human PC-3 prostate cancer cells. Prostate, 26: 260-269, 1995.
36. Boulanger, J , Reyes-Moreno, C., and Koutsilieris, M. Mediation of the glucocorticoid receptor (GR) function by the activation of latent transforming growth factor beta 1 in MG-63 osteoblast-like osteosarcoma cells. Int J. Cancer, 61: 692-697, 1995.
37. Saito, K , Nagashima, M., Iwata, M., Hamada, H., Sumiyoshi, K , Takada, Y., and Takada, A. The concentration of tissue plasminogen activator and urokinase in plasma and tissue of patients with ovarian and uterine tumors. Thromb. Res., 58: 355-366, 1990
38. Shimada, H , Okamura, H , Espey, L. L., and Mori, T. Increase in plasminogen acuvator in the involuting uterus of the postpartum rat. J Endocrinol., 104: 295-298, 1995
39. Gehm, B D , and Rosner, M. R. Regulation of insulin, epidermal growth factor and transforming growth factor-α levels by growth factor-degrading enzymes Endocrinology, 128 1608-1610, 1991
40. Helms, C., Mishra, S. K., Burguess, A. K., Cline, S. L., Knobloch, D., Hing, A. V , Vergnaud, G., and Donis-Keller, H A comprehensive genetic linkage map of the human genome Science (Washington DC), 258: 67-86, 1992